The Cancer Letter asked Patrick Loehrer, director of the Indiana University Melvin & Bren Simon Cancer Center, to discuss his institution's decision to close its 10-year-old proton beam center.
The loss of discounts and rebates hospitals received for administering Genentech's Avastin, Herceptin and Rituxan will increase costs to patients, said Scott Soefje, director of pharmacy at University Medical Center Brackenridge in Austin.
A lobbying campaign will make an effort to secure an immediate, significant funding increase for NIH.
Tumor profiling information Caris Life Sciences provides in its reports isn't backed by sufficient evidence to justify some clinical decisions, said Daniel Hayes, a breast cancer expert at the University of Michigan.
Current controversy over power morcellation points to the importance of multidisciplinary education and consultation, said Monica Bertagnolli, chief of the Division of Surgical Oncology at Brigham and Women's Hospital, and professor of surgery at Harvard Medical School.
The Cancer Letter asked David Challoner, emeritus vice president for health affairs at the University of Florida, to discuss the intricacies and effects of the FDA's 510(k) medical device approval process, and the parties that influence it.
The Cancer Letter asked David Wholley, director of the Foundation for the National Institutes of Health Biomarker Consortium, to explain the novel scientific and administrative structure of Lung-MAP.
The American Cancer Society prefers to avoid public confrontation with corporate donors, even those who make money by selling tobacco products.
I don't see the American Cancer Society on the list. I don't see…
Ella KazerooniThe Cancer Letter asked Ella Kazerooni, a professor of radiology at the University of Michigan, chair of the American College of Radiology Committee on Lung Screening, and vice chair of the lung screening panel of the National Comprehensive Cancer Network, to lay out the rationale for a proposal for broad coverage for lung screening.
